Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen in McCune-Albright Syndrome

Key Takeaways

• FDA grants Rare Pediatric Disease designation to Atossa’s (Z)-endoxifen for McCune-Albright syndrome treatment
• Designation qualifies Atossa for a Priority Review Voucher upon drug approval, potentially worth millions in value
• Expands (Z)-endoxifen development program beyond oncology into rare pediatric endocrine disorders

---

Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease (RPD) designation to (Z)-endoxifen for treating McCune-Albright syndrome, a rare genetic disorder affecting children.

The Seattle-based clinical-stage biopharmaceutical company received this designation on May 4, 2026, marking a significant expansion of its (Z)-endoxifen program beyond oncology applications into rare pediatric endocrine disorders.

Strategic Value of FDA Designation

The RPD designation carries substantial strategic and financial benefits for Atossa. Most notably, it qualifies the company to receive a Priority Review Voucher upon successful drug approval. These vouchers, which can be sold to other pharmaceutical companies, have historically traded for $100-350 million and allow the purchaser to receive priority FDA review for their own drug applications.

About McCune-Albright Syndrome

McCune-Albright syndrome is a rare genetic disorder characterized by fibrous dysplasia of bone, café-au-lait skin pigmentation, and endocrine abnormalities including precocious puberty. The condition affects approximately 1 in 100,000 to 1 in 1 million people, with limited treatment options currently available.

(Z)-Endoxifen Development Program

Atossa’s (Z)-endoxifen represents the active metabolite of tamoxifen, designed to provide more consistent therapeutic effects. The company has been developing this compound primarily for oncology indications, but the McCune-Albright syndrome application demonstrates its potential versatility in treating endocrine-related disorders.

Market Impact and Next Steps

This designation strengthens Atossa’s clinical pipeline and provides additional validation for its (Z)-endoxifen platform. The company will now work toward advancing clinical development in this rare pediatric population while continuing its oncology programs. The RPD designation also provides regulatory incentives including potential tax credits and FDA guidance on clinical trial design.

---

Frequently Asked Questions

What does this FDA designation mean for patients with McCune-Albright syndrome?

The designation accelerates development of a potential new treatment option for this rare condition, which currently has limited therapeutic alternatives. It provides regulatory incentives that may speed the path to approval.

When will (Z)-endoxifen be available for McCune-Albright syndrome patients?

The timeline depends on clinical trial results and regulatory review. The RPD designation provides development incentives, but the drug must still complete clinical trials and receive FDA approval before becoming available to patients.

How valuable is the Priority Review Voucher that Atossa could receive?

Priority Review Vouchers have historically sold for $100-350 million. They allow pharmaceutical companies to receive expedited FDA review of their drug applications, reducing review time from standard 10-12 months to 6-8 months.